For me the exciting news in this announcement is the progress made with the Gen2 device. I consider this device to have much bigger sales potential than Gen1 and to be the big dollar earner for EMV.
The timetable shows expediated FDA approval for Gen2 to be sought in FY25 so I expect product to market in first half of FY26, say 6 months to a year after Gen1.
I am confident the EMV devices work well. We just have to go through the necessary trials and approvals and ensure the devices work as well as possible. I have been in this investment game for many decades and I have never experience such a worthwhile and potentially lucrative investment.
Ann: Product Development Milestones & Grant Funding Achieved, page-16
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.09 |
Change
0.070(3.47%) |
Mkt cap ! $178.7M | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.09 | $2.03 | $42.61K | 20.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $2.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.10 | 3000 | 1 |
View Market Depth
| Last trade - 15.52pm 18/10/2024 (20 minute delay) ? |
| EMV (ASX) Chart |